Application of arterial infusion ports in hepatic arterial infusion chemotherapy and embolization for advanced hepatocellular carcinoma

Xinqiang Han; Peng Zhao; Xuemin Wang; Xiaoyu Tan; Yongzhen Zhang

doi:10.15537/smj.2023.44.12.20230147

References

1.↵
1. Sung H,
2. Ferlay J,
3. Siegel RL,
4. Laversanne M,
5. Soerjomataram I,
6. Jemal A, et al.
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249.
OpenUrl CrossRef PubMed
2.↵
The Guideline Committee of the Chinese Society of Clinical Oncology (CSCO). Guidelines of Chinese Society of Clinical Oncology (CSCO): hepatocellular carcinoma. People’s Med Publishing House 2020; 4: 59-70.
3.↵
The General Office of the National Health Commission of the People’s Republic of China. Standardization for diagnosis and treatment of hepatocellular carcinoma. J Clin Hepatol 2022; 38: 288-303.
OpenUrl
4.↵
1. Kudo M,
2. Cheng AL,
3. Park JW,
4. Park JH,
5. Liang PC,
6. Hidaka H, et al.
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol 2018; 3: 37-46.
OpenUrl
5.↵
1. Ikeda M,
2. Arai Y,
3. Inaba Y,
4. Tanaka T,
5. Sugawara S,
6. Kodama Y, et al.
Conventional or drug-eluting beads? Randomized controlled study of chemoembolization for hepatocellular carcinoma: JIVROSG-1302. Liver Cancer 2022; 11: 440-450.
OpenUrl
6.↵
1. Chen S,
2. Yu W,
3. Zhang K,
4. Liu W,
5. Chen C.
Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma. Hepatol Res 2021;51: 482-489.
OpenUrl
7.↵
1. Liu PH,
2. Huo TI,
3. Miksad RA.
Hepatocellular carcinoma with portal vein tumor involvement: best management strategies. Semin Liver Dis 2018; 38: 242-251.
OpenUrl
8.↵
1. Li QJ,
2. He MK,
3. Chen HW,
4. Fang WQ,
5. Zhou YM,
6. Xu L, et al.
Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol 2022; 40: 150-160.
OpenUrl
9.↵
1. Lyu N,
2. Wang X,
3. Li JB,
4. Lai JF,
5. Chen QF,
6. Li SL, et al.
Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase iii trial (fohaic-1). J Clin Oncol 2022; 40: 468-480.
OpenUrl
10.↵
1. Kodama K,
2. Kawaoka T,
3. Aikata H,
4. Uchikawa S,
5. Inagaki Y,
6. Hatooka M, et al.
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. J Gastroenterol Hepatol 2018; 33: 1780-1786.
OpenUrl
11.↵
1. Ikeda M,
2. Morizane C,
3. Ueno M,
4. Okusaka T,
5. Ishii H,
6. Furuse J.
Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol 2018; 48: 103-114.
OpenUrl CrossRef PubMed
12.↵
1. He MK,
2. Le Y,
3. Li QJ,
4. Yu ZS,
5. Li SH,
6. Wei W, et al.
Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chin J Cancer 2017; 36: 83.
OpenUrl
13.↵
1. Lyu N,
2. Kong Y,
3. Mu L,
4. Lin Y,
5. Li J,
6. Liu Y, et al.
Hepatic arterial infusion of oxaliplatin plus fluorouracil/ leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol 2018; 69: 60-69.
OpenUrl
14.↵
1. Marrero JA,
2. Kulik LM,
3. Sirlin CB,
4. Zhu AX,
5. Finn RS,
6. Abecassis MM, et al.
Diagnosis, staging, and management of hepatocellular carcinoma: practice guidance by the american association for the study of liver diseases. Hepatology 2018; 68: 723-750.
OpenUrl CrossRef PubMed
15.↵
1. Casanova AG,
2. Hernández-Sánchez MT,
3. López-Hernández FJ,
4. Martínez-Salgado C,
5. Prieto M,
6. Vicente-Vicente L, et al.
Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity. Eur J Clin Pharmacol 2020; 76: 23-33.
OpenUrl
16.↵
Gynecological Oncology Society of Chinese Medical Association. Clinical practice guidelines on platinum therapy in gynecological tumors. Med J Peking Union Med Coll Hosp 2021; 12: 881-901.
OpenUrl
17.↵
1. Zhao X,
2. Sun X,
3. Jing J,
4. Zhou H,
5. Jin Y.
Safety study of Folfox-HAIC in relieving bed restriction. J Interv Med 2021; 4: 203-207.
OpenUrl
18.↵
1. Chen MS,
2. Yuan YF,
3. Guo RP,
4. Shi M,
5. Huang JH, et al.
Application of hepatic arterial infusion chemotherapy in the conversion therapy of hepatocellular carcinoma—experience of Sun Yat-sen University Cancer Center. Chin J Front Med Sci 2021; 13: 70-76.
OpenUrl
19.↵
1. Shi M,
2. He MK,
3. Chen MS.
Current status and future perspective of hepatic artery infusion chemotherapy. J Surg Concept Prac 2020; 25: 10-14.
OpenUrl
20.↵
1. Mu XM,
2. Wang W,
3. Jiang YY,
4. Feng J.
Patterns of Comorbidity in Hepatocellular Carcinoma: A Network Perspective. Int J Environ Res Public Health 2020;17: 3108.
OpenUrl
21.↵
1. Rassi AB,
2. d’Amico EA,
3. Tripodi A,
4. da Rocha TRF,
5. Migita BY,
6. Ferreira CM, et al.
Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation. J Hepatol 2020; 72: 85-94.
OpenUrl CrossRef PubMed
22.↵
1. Fujita M,
2. Okai K,
3. Hayashi M,
4. Abe K,
5. Takahashi A,
6. Kimura T, et al.
Huge hepatocellular carcinoma treated with radical hepatectomy after drug-eluting bead transarterial chemoembolization. Intern Med 2019; 58: 1103-1110.
OpenUrl
23.↵
1. Kondo M,
2. Morimoto M,
3. Kobayashi S,
4. Ohkawa S,
5. Hidaka H,
6. Nakazawa T, et al.
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. BMC Cancer 2019; 19: 954.
OpenUrl
24.↵
1. Qin S,
2. Kruger E,
3. Tan SC,
4. Cheng S,
5. Wang N,
6. Liang J.
Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. Cost Eff Resour Alloc 2018; 16: 29.
OpenUrl
25.↵
1. Chaudhry S,
2. Fields RC,
3. Grierson PM,
4. Lim KH.
Combined systemic and hepatic artery infusion pump chemo-therapy as a liver-directed therapy for colorectal liver metastasis-review of literature and case discussion. Cancers (Basel) 2021; 13: 1283.
OpenUrl
26.↵
1. Hu J,
2. Cao G,
3. Xu L,
4. Zheng K,
5. Zhu X,
6. Yang R, et al.
Retrograde embolization technique of the right gastric artery during the implantation of port-catheter system for hepatic arterial infusion chemotherapy. J Interv Med 2020; 12; 4: 27-31.
OpenUrl
27.↵
1. Hu J,
2. Zhu X,
3. Wang X,
4. Cao G,
5. Wang X,
6. Yang R.
Evaluation of percutaneous unilateral trans-femoral implantation of side-hole port-catheter system with coil only fixed-catheter-tip for hepatic arterial infusion chemotherapy. Cancer Imaging 2019; 19: 15.
OpenUrl
28.↵
1. Kudo M,
2. Ueshima K,
3. Yokosuka O,
4. Ogasawara S,
5. Obi S,
6. Izumi N, et al.
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol 2018; 3: 424-432.
OpenUrl
29.↵
1. Lyu N,
2. Kong Y,
3. Pan T,
4. Mu L,
5. Li S,
6. Liu Y, et al.
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. J Vasc Interv Radiol 2019; 30: 349-357.e2.
OpenUrl

In this issue

Download PDF

Email Article

Citation Tools

Bookmark this article

Cited By...

No citing articles found.

Google Scholar

More in this TOC Section

Show more Original Article

Keywords

[1] 1.↵
Sung H,
Ferlay J,
Siegel RL,
Laversanne M,
Soerjomataram I,
Jemal A, et al.
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249.
OpenUrl CrossRef PubMed

[2] Sung H,

[3] Ferlay J,

[4] Siegel RL,

[5] Laversanne M,

[6] Soerjomataram I,

[7] Jemal A, et al.

[8] 2.↵
The Guideline Committee of the Chinese Society of Clinical Oncology (CSCO). Guidelines of Chinese Society of Clinical Oncology (CSCO): hepatocellular carcinoma. People’s Med Publishing House 2020; 4: 59-70.

[9] 3.↵
The General Office of the National Health Commission of the People’s Republic of China. Standardization for diagnosis and treatment of hepatocellular carcinoma. J Clin Hepatol 2022; 38: 288-303.
OpenUrl

[10] 4.↵
Kudo M,
Cheng AL,
Park JW,
Park JH,
Liang PC,
Hidaka H, et al.
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol 2018; 3: 37-46.
OpenUrl

[11] Kudo M,

[12] Cheng AL,

[13] Park JW,

[14] Park JH,

[15] Liang PC,

[16] Hidaka H, et al.

[17] 5.↵
Ikeda M,
Arai Y,
Inaba Y,
Tanaka T,
Sugawara S,
Kodama Y, et al.
Conventional or drug-eluting beads? Randomized controlled study of chemoembolization for hepatocellular carcinoma: JIVROSG-1302. Liver Cancer 2022; 11: 440-450.
OpenUrl

[18] Ikeda M,

[19] Arai Y,

[20] Inaba Y,

[21] Tanaka T,

[22] Sugawara S,

[23] Kodama Y, et al.

[24] 6.↵
Chen S,
Yu W,
Zhang K,
Liu W,
Chen C.
Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma. Hepatol Res 2021;51: 482-489.
OpenUrl

[25] Chen S,

[26] Yu W,

[27] Zhang K,

[28] Liu W,

[29] Chen C.

[30] 7.↵
Liu PH,
Huo TI,
Miksad RA.
Hepatocellular carcinoma with portal vein tumor involvement: best management strategies. Semin Liver Dis 2018; 38: 242-251.
OpenUrl

[31] Liu PH,

[32] Huo TI,

[33] Miksad RA.

[34] 8.↵
Li QJ,
He MK,
Chen HW,
Fang WQ,
Zhou YM,
Xu L, et al.
Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol 2022; 40: 150-160.
OpenUrl

[35] Li QJ,

[36] He MK,

[37] Chen HW,

[38] Fang WQ,

[39] Zhou YM,

[40] Xu L, et al.

[41] 9.↵
Lyu N,
Wang X,
Li JB,
Lai JF,
Chen QF,
Li SL, et al.
Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase iii trial (fohaic-1). J Clin Oncol 2022; 40: 468-480.
OpenUrl

[42] Lyu N,

[43] Wang X,

[44] Li JB,

[45] Lai JF,

[46] Chen QF,

[47] Li SL, et al.

[48] 10.↵
Kodama K,
Kawaoka T,
Aikata H,
Uchikawa S,
Inagaki Y,
Hatooka M, et al.
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. J Gastroenterol Hepatol 2018; 33: 1780-1786.
OpenUrl

[49] Kodama K,

[50] Kawaoka T,

[51] Aikata H,

[52] Uchikawa S,

[53] Inagaki Y,

[54] Hatooka M, et al.

[55] 11.↵
Ikeda M,
Morizane C,
Ueno M,
Okusaka T,
Ishii H,
Furuse J.
Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol 2018; 48: 103-114.
OpenUrl CrossRef PubMed

[56] Ikeda M,

[57] Morizane C,

[58] Ueno M,

[59] Okusaka T,

[60] Ishii H,

[61] Furuse J.

[62] 12.↵
He MK,
Le Y,
Li QJ,
Yu ZS,
Li SH,
Wei W, et al.
Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chin J Cancer 2017; 36: 83.
OpenUrl

[63] He MK,

[64] Le Y,

[65] Li QJ,

[66] Yu ZS,

[67] Li SH,

[68] Wei W, et al.

[69] 13.↵
Lyu N,
Kong Y,
Mu L,
Lin Y,
Li J,
Liu Y, et al.
Hepatic arterial infusion of oxaliplatin plus fluorouracil/ leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol 2018; 69: 60-69.
OpenUrl

[70] Lyu N,

[71] Kong Y,

[72] Mu L,

[73] Lin Y,

[74] Li J,

[75] Liu Y, et al.

[76] 14.↵
Marrero JA,
Kulik LM,
Sirlin CB,
Zhu AX,
Finn RS,
Abecassis MM, et al.
Diagnosis, staging, and management of hepatocellular carcinoma: practice guidance by the american association for the study of liver diseases. Hepatology 2018; 68: 723-750.
OpenUrl CrossRef PubMed

[77] Marrero JA,

[78] Kulik LM,

[79] Sirlin CB,

[80] Zhu AX,

[81] Finn RS,

[82] Abecassis MM, et al.

[83] 15.↵
Casanova AG,
Hernández-Sánchez MT,
López-Hernández FJ,
Martínez-Salgado C,
Prieto M,
Vicente-Vicente L, et al.
Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity. Eur J Clin Pharmacol 2020; 76: 23-33.
OpenUrl

[84] Casanova AG,

[85] Hernández-Sánchez MT,

[86] López-Hernández FJ,

[87] Martínez-Salgado C,

[88] Prieto M,

[89] Vicente-Vicente L, et al.

[90] 16.↵
Gynecological Oncology Society of Chinese Medical Association. Clinical practice guidelines on platinum therapy in gynecological tumors. Med J Peking Union Med Coll Hosp 2021; 12: 881-901.
OpenUrl

[91] 17.↵
Zhao X,
Sun X,
Jing J,
Zhou H,
Jin Y.
Safety study of Folfox-HAIC in relieving bed restriction. J Interv Med 2021; 4: 203-207.
OpenUrl

[92] Zhao X,

[93] Sun X,

[94] Jing J,

[95] Zhou H,

[96] Jin Y.

[97] 18.↵
Chen MS,
Yuan YF,
Guo RP,
Shi M,
Huang JH, et al.
Application of hepatic arterial infusion chemotherapy in the conversion therapy of hepatocellular carcinoma—experience of Sun Yat-sen University Cancer Center. Chin J Front Med Sci 2021; 13: 70-76.
OpenUrl

[98] Chen MS,

[99] Yuan YF,

[100] Guo RP,

[101] Shi M,

[102] Huang JH, et al.

[103] 19.↵
Shi M,
He MK,
Chen MS.
Current status and future perspective of hepatic artery infusion chemotherapy. J Surg Concept Prac 2020; 25: 10-14.
OpenUrl

[104] Shi M,

[105] He MK,

[106] Chen MS.

[107] 20.↵
Mu XM,
Wang W,
Jiang YY,
Feng J.
Patterns of Comorbidity in Hepatocellular Carcinoma: A Network Perspective. Int J Environ Res Public Health 2020;17: 3108.
OpenUrl

[108] Mu XM,

[109] Wang W,

[110] Jiang YY,

[111] Feng J.

[112] 21.↵
Rassi AB,
d’Amico EA,
Tripodi A,
da Rocha TRF,
Migita BY,
Ferreira CM, et al.
Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation. J Hepatol 2020; 72: 85-94.
OpenUrl CrossRef PubMed

[113] Rassi AB,

[114] d’Amico EA,

[115] Tripodi A,

[116] da Rocha TRF,

[117] Migita BY,

[118] Ferreira CM, et al.

[119] 22.↵
Fujita M,
Okai K,
Hayashi M,
Abe K,
Takahashi A,
Kimura T, et al.
Huge hepatocellular carcinoma treated with radical hepatectomy after drug-eluting bead transarterial chemoembolization. Intern Med 2019; 58: 1103-1110.
OpenUrl

[120] Fujita M,

[121] Okai K,

[122] Hayashi M,

[123] Abe K,

[124] Takahashi A,

[125] Kimura T, et al.

[126] 23.↵
Kondo M,
Morimoto M,
Kobayashi S,
Ohkawa S,
Hidaka H,
Nakazawa T, et al.
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. BMC Cancer 2019; 19: 954.
OpenUrl

[127] Kondo M,

[128] Morimoto M,

[129] Kobayashi S,

[130] Ohkawa S,

[131] Hidaka H,

[132] Nakazawa T, et al.

[133] 24.↵
Qin S,
Kruger E,
Tan SC,
Cheng S,
Wang N,
Liang J.
Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. Cost Eff Resour Alloc 2018; 16: 29.
OpenUrl

[134] Qin S,

[135] Kruger E,

[136] Tan SC,

[137] Cheng S,

[138] Wang N,

[139] Liang J.

[140] 25.↵
Chaudhry S,
Fields RC,
Grierson PM,
Lim KH.
Combined systemic and hepatic artery infusion pump chemo-therapy as a liver-directed therapy for colorectal liver metastasis-review of literature and case discussion. Cancers (Basel) 2021; 13: 1283.
OpenUrl

[141] Chaudhry S,

[142] Fields RC,

[143] Grierson PM,

[144] Lim KH.

[145] 26.↵
Hu J,
Cao G,
Xu L,
Zheng K,
Zhu X,
Yang R, et al.
Retrograde embolization technique of the right gastric artery during the implantation of port-catheter system for hepatic arterial infusion chemotherapy. J Interv Med 2020; 12; 4: 27-31.
OpenUrl

[146] Hu J,

[147] Cao G,

[148] Xu L,

[149] Zheng K,

[150] Zhu X,

[151] Yang R, et al.

[152] 27.↵
Hu J,
Zhu X,
Wang X,
Cao G,
Wang X,
Yang R.
Evaluation of percutaneous unilateral trans-femoral implantation of side-hole port-catheter system with coil only fixed-catheter-tip for hepatic arterial infusion chemotherapy. Cancer Imaging 2019; 19: 15.
OpenUrl

[153] Hu J,

[154] Zhu X,

[155] Wang X,

[156] Cao G,

[157] Wang X,

[158] Yang R.

[159] 28.↵
Kudo M,
Ueshima K,
Yokosuka O,
Ogasawara S,
Obi S,
Izumi N, et al.
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol 2018; 3: 424-432.
OpenUrl

[160] Kudo M,

[161] Ueshima K,

[162] Yokosuka O,

[163] Ogasawara S,

[164] Obi S,

[165] Izumi N, et al.

[166] 29.↵
Lyu N,
Kong Y,
Pan T,
Mu L,
Li S,
Liu Y, et al.
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. J Vasc Interv Radiol 2019; 30: 349-357.e2.
OpenUrl

[167] Lyu N,

[168] Kong Y,

[169] Pan T,

[170] Mu L,

[171] Li S,

[172] Liu Y, et al.

Main menu

User menu

Search

Application of arterial infusion ports in hepatic arterial infusion chemotherapy and embolization for advanced hepatocellular carcinoma

References

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS

Main menu

User menu

Search

Application of arterial infusion ports in hepatic arterial infusion chemotherapy and embolization for advanced hepatocellular carcinoma

References

In this issue

Citation Manager Formats

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

CONTENT

JOURNAL

AUTHORS